{"filings":[{"id":1389196,"accession_number":"0001493152-26-031564","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K12B","filed_at":"2026-07-01T20:43:06+00:00","items":["1.01","3.01","8.01","3.03","5.01","5.02","5.03","9.01"],"status":"ready","headline":"ChronoScale Corporation reorganizes into holding company structure, becomes ChronoScale Holdings Corporation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On July 1, 2026, ChronoScale completed a holding company reorganization, merging with a subsidiary of newly formed ChronoScale Holdings.","Each outstanding share of ChronoScale common stock was automatically converted into one share of ChronoScale Holdings common stock.","ChronoScale Holdings became the successor issuer under Rule 12g-3(a) and will continue trading on Nasdaq under ticker CHRN.","Andrew Schaap was appointed to the Board of Directors on June 29, 2026.","ChronoScale contributed all equity of its subsidiary Applied Digital Cloud Corporation to ChronoScale Holdings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1362836,"accession_number":"0001493152-26-031317","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K/A","filed_at":"2026-06-30T21:14:44+00:00","items":["9.01","8.01"],"status":"ready","headline":"ChronoScale files Cloud financials: FY2025 revenue $84.4M, net loss $72.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cloud FY2025 revenue $84.4M (up from $29.0M in FY2024); net loss $72.7M vs $75.3M prior year.","Cloud operating loss $55.3M in FY2025; cost of revenues $115.3M exceeded revenue.","Cloud had $12M SAFE agreement debt as of May 31, 2025; total assets $304.2M.","Pro forma unaudited combined financials as of Feb 28, 2026 filed as Exhibit 99.3.","Business combination closed May 5, 2026; ChronoScale (f/k/a Ekso Bionics) now owns Cloud."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1361916,"accession_number":"0001493152-26-031298","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2026-06-30T20:43:26+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"ChronoScale appoints Andrew Schaap to board, grants 200,000 restricted shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 7 to 8 members; Schaap appointed effective June 29, 2026.","Schaap joins Audit Committee (replacing Douglas Miller) and Related Party Transactions Committee.","Schaap receives 200,000 restricted shares vesting 50% on each of first two anniversaries.","Subsidiary has a data center lease with a company where Schaap is CEO; lease was in ordinary course."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1305716,"accession_number":"0001493152-26-030318","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2026-06-26T20:50:18+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"ChronoScale enters $100M unsecured demand note from Applied Digital Corporation","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Applied Digital Corporation makes $100M unsecured demand grid promissory note available to ChronoScale.","Interest rate equals short-term Applicable Federal Rate (AFR), compounded semiannually; note is non-convertible.","No advances drawn to date; proceeds to be used for working capital and general corporate purposes.","Lender and its affiliate hold approx. 96% of ChronoScale common stock; transaction approved by related party committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":861321,"accession_number":"0001493152-26-027271","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2026-06-04T20:15:33+00:00","items":["2.05"],"status":"ready","headline":"Chronoscale plans to divest Ekso Bionics, focus on cloud business","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board committed on May 29, 2026 to divest wholly owned subsidiary Ekso Bionics, Inc.","Company will focus solely on cloud business; expects divestiture completion in first fiscal quarter.","Material charges expected: severance, lease termination, transaction costs; estimate not yet available.","Company will amend 8-K with cost estimates within four business days as required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":556760,"accession_number":"0001493152-26-024664","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K/A","filed_at":"2026-05-20T21:14:33+00:00","items":["5.02","9.01"],"status":"ready","headline":"ChronoScale Amends Phantom PSU Awards for Three Executives After Change in Control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Scott Davis's Phantom PSU amended to settle as 109,357 shares of common stock plus $1,000,000 cash.","Jerome Wong's Phantom PSU amended to settle entirely in 40,000 shares of common stock.","Jason Jones's Phantom PSU amended to settle entirely in 32,000 shares of common stock.","Amendments follow May 5, 2026 closing of Contribution and Exchange Agreement with Applied Digital Cloud Corp.","Phantom PSUs originally granted Nov 5, 2025 vested upon achieving Stock Price Goal and Change in Control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93567,"accession_number":"0001493152-26-021330","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K/A","filed_at":"2026-05-05T23:59:59+00:00","items":["1.01","2.01","2.02","3.02","3.03","4.01","5.01","5.02","5.03","9.01"],"status":"ready","headline":"Ekso Bionics completes reverse merger with Applied Digital subsidiary; renames to ChronoScale Corp.","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Applied Parent & Contributor now hold ~97% of outstanding shares; legacy Ekso holders retain ~3%.","Company issued 138,216,820 new shares to Contributor for 100% of Cloud; post-merger shares outstanding 143,093,381.","Applied Parent invested $15.75M via PIPE at $12.01/share, receiving 1,311,407 shares.","Board reconstituted with 4 APLD designees (Wes Cummins as Chairman); ticker changes to 'CHRN' on Nasdaq.","Fiscal year end changed to May 31; authorized common shares increased to 290M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93568,"accession_number":"0001493152-26-021099","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"Ekso Bionics to close business combination with Applied Digital, PIPE $15.75M, ticker becomes CHRN","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Business combination with Applied Digital subsidiary closes May 5, 2026; company renames to ChronoScale Corporation.","Applied Digital (parent) buys 1,311,407 shares at $12.01/share in PIPE, gross proceeds ~$15.75M.","New ticker symbol 'CHRN' on Nasdaq; CUSIP changes to 170924104.","Lake Street Capital Markets serves as placement agent, receives 5% cash fee (~$0.75M)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105299,"accession_number":"0001437749-26-004205","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["1.01","2.02","3.02","3.03","5.03","5.01","5.02","9.01"],"status":"ready","headline":"Ekso to merge with Applied Digital Cloud in reverse merger; APLD to own ~97%, rename to ChronoScale","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exchange: Ekso issues 138.2M shares to APLD for 100% of Cloud; APLD expects ~97% ownership of combined company.","Closing expected Q2 2026, subject to stockholder approval, SEC clearance, and minimum $15M cash condition including PIPE.","Preliminary Q4 2025 revenue $3.0-3.1M, down from $5.1M YoY; gross margin ~52-53%; cash $1.2M as of Dec 31, 2025.","Company used ~$4.3M net cash in operations in Q4 2025, vs $1.4M in Q4 2024; cash excludes Jan 2026 PIPE proceeds.","Board to be chaired by Wes Cummins (APLD); other initial APLD designees: Jason Zhang, Ella Benson, Richard Nottenburg."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105298,"accession_number":"0001437749-26-001774","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"Ekso Bionics raises ~$5.3M net via private placement of Series B convertible preferred and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 5,852 shares of Series B Convertible Preferred Stock (stated value $1,000/share) and warrants for 355,960 shares.","Conversion price and warrant exercise price set at $8.22 per share of common stock; 6-month lock-up on transfers.","Net proceeds of ~$5.3M after ~$0.4M placement agent fees; intended for working capital and general corporate purposes.","Filed Certificate of Designation for Series B Preferred with Nevada Secretary of State on January 22, 2026.","Lake Street Capital Markets acted as exclusive placement agent; received a 6% cash fee and a warrant for 14,238 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121576,"accession_number":"0001437749-25-038864","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Ekso Bionics and Applied Digital propose business combination; EKSO holders get ~3% of ChronoScale","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Applied Digital to spin out cloud business, combine with EKSO to form ChronoScale Corporation.","Upon closing, Applied Digital would own ~97% of combined company; EKSO existing stockholders ~3%.","EKSO plans to explore sale of all or substantially all of its current business.","Applied Digital Cloud generated ~$75.2M revenue in TTM ending Aug 31, 2025.","Proposed transaction expected to close in first half of 2026, subject to approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121575,"accession_number":"0001437749-25-033889","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ekso Bionics awards 114.5k RSUs and 257k phantom PSUs to Davis, Wong, Jones; new severance deals","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Davis: 80k RSUs + 185k phantom PSUs; severance 9 months (non-CIC) or 18 months salary (CIC).","Jerome Wong: 19.5k RSUs + 40k phantom PSUs; severance 6 months (non-CIC) or 9 months salary (CIC).","Jason Jones: 15k RSUs + 32k phantom PSUs; severance 6 months (non-CIC) or 9 months salary (CIC).","Phantom PSUs vest only upon Change in Control and stock price ≥$7.50; settled in cash, not shares.","All RSU grants fully vested as of grant date; phantom PSUs have a 5-year performance period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121574,"accession_number":"0001437749-25-032276","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Ekso Bionics raises $3.2M net in registered direct offering of 769,490 shares at $4.81","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 769,490 shares at $4.81 per share to institutional investors; net proceeds ~$3.2M.","Closing expected on or about October 30, 2025, subject to customary conditions.","Proceeds for general corporate purposes: R&D, SG&A, and working capital.","Issued placement agent warrant to Lake Street Capital Markets for 15,389 shares at $4.81.","Offering conducted under existing effective shelf registration statement (File No. 333-272607)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121573,"accession_number":"0001437749-25-031957","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ekso Bionics Q3 revenue $4.2M (+2% YoY); exploring sale or acquisition of different industry","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revenue $4.2M, up 2% YoY and 105% sequentially; gross margin 60.3% vs 53.5% last year.","Net loss narrowed 31% YoY to $1.4M ($0.54/share) from $2.1M ($1.53/share).","Cash $2.7M as of Sept 30, 2025.","Company exploring strategic transactions including acquisition of a non-exoskeleton business or sale of substantially all assets.","Any transaction would require stockholder approval; no timetable set for strategic review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138234,"accession_number":"0001437749-25-029285","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Ekso Bionics enters $2M secured loan with B. Riley at 10% interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Agreement with B. Riley Commercial Capital for up to $2.0M secured term loan, maturing Sept 14, 2026 or upon qualified equity raise of $2.4M.","Interest at 10% per annum; exit fee of $200K (10% of principal) due at maturity.","Loan may convert into equity in connection with a qualified financing at the lead investor's price.","Existing $2.0M loan from Banc of California (Pacific Western Bank) terminated and fully paid off.","Proceeds for working capital and general corporate purposes; secured by substantially all personal property of company and subsidiary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138233,"accession_number":"0001437749-25-023643","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ekso Bionics Q2 revenue falls 58% YoY to $2.1M; net loss $2.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.1M vs $5.0M in Q2 2024, down 58% due to lower Enterprise Health device sales.","Gross margin 40% vs 53% prior year; gross profit $0.8M vs $2.6M.","Net loss $2.7M ($1.24/share) vs $2.4M ($1.99/share) in Q2 2024.","Personal Health device sales grew >50% YoY in H1 2025; cash $5.2M at June 30.","Named Bionic P&O as first Ekso Indego Personal distributor; joined NVIDIA Connect program."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":5432000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155684,"accession_number":"0001437749-25-018005","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ekso Bionics updates reverse stock split effective date to June 2, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-15 effective June 2, 2025; originally planned May 27.","Approved by shareholders on May 16; aims to regain Nasdaq $1.00 minimum bid price.","Pre-split shares ~35.5M; post-split ~2.4M outstanding; fractional shares rounded up.","Common stock to trade on Nasdaq under symbol EKSO on split-adjusted basis.","New CUSIP number 282644 400 will apply after the split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155683,"accession_number":"0001437749-25-017680","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Ekso Bionics approves 1-for-15 reverse stock split effective May 27, 2025 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio set at 1-for-15; effective 12:01 a.m. PT on May 27, 2025.","Post-split shares ~2.35M vs pre-split ~35.3M; par value unchanged at $0.001.","Stock will trade on Nasdaq (symbol EKSO) on split-adjusted basis; new CUSIP 282644400.","Fractional shares rounded up to next whole share; no proportional cut in authorized shares.","Purpose: raise per-share price to meet $1 minimum bid for 10 consecutive trading days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155682,"accession_number":"0001437749-25-014527","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ekso Bionics Q1 2025 revenue $3.4M, net loss $2.9M; partnerships expand distribution","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $3.4M down 11% YoY ($3.8M); net loss $2.9M ($0.12/sh) vs $3.4M ($0.20/sh) in Q1 2024.","Gross margin improved to 53.5% from 51.9%; cash used in operations fell 43% to $2.0M.","Named National Seating & Mobility as exclusive U.S. CRT distributor for Ekso Indego Personal.","Appointed Bionic Prosthetics & Orthotics Group as first O&P distributor for Ekso Indego Personal.","Cash and restricted cash $8.1M at March 31, 2025; $3.8M net proceeds from warrant exercises."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":3375000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174169,"accession_number":"0001437749-25-007795","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["1.01","3.02","3.03","9.01"],"status":"ready","headline":"Ekso Bionics raises $4.15M via warrant exercise; issues new 10.5M-share warrant at $0.4239","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing holder exercises 9.8M warrants for $4.15M at $0.4239/share; company receives cash proceeds.","Company issues new warrant for 10.5M shares at $0.4239/share, exercisable upon stockholder approval due by July 15, 2025.","Company agrees to share issuance standstill until May 31, 2025; no variable rate transactions until Sept 13, 2025.","New warrant has 4.99% beneficial ownership limit (holder may increase to 9.99% with 61 days' notice).","Company must file resale registration statement for new warrant shares within 30 days of stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174168,"accession_number":"0001437749-25-005911","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ekso Bionics reports record Q4 revenue $5.1M, net loss improves 25% for FY 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $5.1M, up 5% YoY; gross margin 53%, up 400 bps vs 49% in Q4 2023.","FY 2024 revenue $17.9M, down 2% YoY; net loss $11.3M ($0.56/sh), 25% better than FY 2023.","Cash and restricted cash $6.5M at Dec 31, 2024; operating cash burn improved to $9.8M from $12.1M.","Post-year-end, named National Seating & Mobility exclusive U.S. distributor for Ekso Indego Personal device."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174167,"accession_number":"0001437749-25-000928","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Ekso Bionics expects record Q4 2024 revenue of $5.0-$5.1M, preliminary","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q4 2024 revenue estimated at $5.0-5.1M (company record vs $4.8M in Q4 2023).","Cash $6.5M at Dec 31, 2024, down from $8.6M a year earlier.","Net cash used in ops Q4 2024 estimated $1.5M, improving from $1.6M year ago.","CEO highlights initial CMS reimbursement for Ekso Indego Personal device.","Full Q4 and FY 2024 results expected in first week of March 2025."],"consensus_eps_estimate":-0.2907,"consensus_eps_actual":-8.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":17925000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191114,"accession_number":"0001437749-24-037475","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ekso Bionics receives Nasdaq bid price deficiency notice; has until June 10, 2025 to comply","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice dated Dec 12, 2024: common stock bid price below $1.00 for 31 consecutive business days.","Company has 180 calendar days, until June 10, 2025, to regain compliance under Nasdaq Listing Rule 5810(c)(3)(A).","To regain compliance, closing bid price must be $1.00 or more for at least ten consecutive business days.","If not cured by June 10, 2025, Company may seek a second 180-day period if meeting all other initial listing standards and intends a reverse stock split.","Failure to regain compliance or secure extension could result in delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191113,"accession_number":"0001437749-24-032290","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ekso Bionics Q3 rev $4.1M (-11% YoY), loss narrows; announces CMS reimbursement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.1M (Q3 2024) vs $4.6M (Q3 2023); 33 EksoHealth devices sold.","Gross margin improved to 53.5% from 53.3% on supply chain cost savings.","Net loss narrowed to $2.1M ($0.10/share) from $3.4M ($0.24/share) YoY.","Received CMS reimbursement for Ekso Indego Personal, enabling Medicare coverage for SCI patients.","Cash $8.3M at Sep 30, 2024; raised $5.0M net in underwritten offering during September."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":12835000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207583,"accession_number":"0001437749-24-028253","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ekso Bionics raises ~$5.1M net in underwritten public offering of units with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 3.1M units at $1.00/unit (share + Series A/B warrants) and 2.9M pre-funded units at $0.9990/unit.","Net proceeds after underwriting discount and expenses were approximately $5.1 million.","Each Series A and B warrant exercisable at $1.00 per share; pre-funded warrants at $0.001.","Executive officers and directors subject to 90-day lock-up on common stock sales.","Underwriter is Craig-Hallum Capital Group."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207582,"accession_number":"0001437749-24-023753","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ekso Bionics reports record Q2 sales of $5.0M; net loss narrows to $0.13 per share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $5.0M up 5% YoY; gross margin improved to 53% from 48%.","Net loss $2.4M ($0.13/sh) vs $4.2M ($0.31/sh) in Q2 2023, narrowing significantly.","Sold 37 EksoHealth devices in Q2; initial Medicare claims for Ekso Indego Personal pending.","Operating expenses decreased across all categories: SG&A down 21%, R&D down 20%, G&A down 28%.","Cash at June 30, 2024 $5.9M, down from $8.6M at Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":8706000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207581,"accession_number":"0001437749-24-023606","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K/A","filed_at":"2024-07-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ekso Bionics board elects annual say-on-pay vote after stockholder advisory frequency vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board determined on July 25, 2024 to hold future advisory votes on executive compensation annually.","Frequency matches board's proxy recommendation and stockholder vote at June 6, 2024 annual meeting.","Decision disclosed via 8-K/A amendment to report the frequency determination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225029,"accession_number":"0001437749-24-019834","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ekso Bionics shareholders approve all proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected: Scott Davis, Mary Ann Cloyd, Corinna Lathan, Charles Li, Deborah Lafer Scher.","Equity incentive plan extended to April 2034; authorized shares increased to 4,724,286 (1M increase).","Advisory say-on-pay approved: 6,303,399 for, 631,663 against, 124,065 abstained.","Annual frequency for future advisory votes selected: 6,840,255 for 1 year.","WithumSmith+Brown ratified as auditor for FY2024: 11,245,624 for, 153,991 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225028,"accession_number":"0001437749-24-013687","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ekso Bionics Q1 revenue $3.8M; net loss narrows; CMS Medicare reimbursement for Indego Personal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.8M (down 7% YoY from $4.1M); gross margin improved to 52% from 49%.","Net loss narrowed to $3.4M ($0.20 per share) compared to $4.4M ($0.33) in Q1 2023.","CMS issued final Medicare payment determination for Ekso Indego Personal, enabling reimbursement.","Sold 29 EksoHealth units in Q1; cash and restricted cash $8.8M at March 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":3756000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244265,"accession_number":"0001437749-24-006421","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ekso Bionics reports record 2023 revenue of $18.3M, up 42% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2023 revenue $18.3M (FY22: $12.9M); sold 151 EksoHealth units.","Q4 2023 revenue $4.8M (+36% YoY); gross margin 49% vs 47%.","Net loss FY23 $15.2M ($1.10/sh) vs $15.1M ($1.16/sh) in FY22.","Cash at Dec 31, 2023: $8.6M, down from $20.5M; raised $3.9M in Jan 2024 offering.","CMS deferred payment determination for personal exoskeletons (Ekso Indego Personal)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244264,"accession_number":"0001437749-24-001348","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ekso Bionics raises ~$4.0M in registered direct offering of 2.97M shares at $1.55/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 2,967,742 common shares at $1.55 each; net proceeds ~$4.0M after fees and expenses.","Offering closed on January 16, 2024; proceeds for general corporate purposes (R&D, SG&A, working capital).","Exercise price of May 2019 warrants (193,060 outstanding) reduced from $3.52 to $1.55 per share due to anti-dilution.","A.G.P./Alliance Global Partners acted as exclusive placement agent; fee of 7% of gross proceeds plus expense reimbursements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244263,"accession_number":"0001437749-24-001129","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Ekso Bionics files consent of independent auditor; no material news disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed Exhibit 23.1: Consent of WithumSmith+Brown, PC, independent registered public accounting firm.","Consent relates to incorporation by reference of audited financials into registration statements.","No earnings, M&A, leadership changes, or other material events reported.","Filing is procedural and lacks substantive financial or operational details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244262,"accession_number":"0001437749-24-000621","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Ekso Bionics prelim Q4 rev ~$4.8M (+31% YoY); FY rev ~$18.2M (+41% YoY); cash $8.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue estimated $4.7-4.9M, up from $3.6M in Q4 2022 (30-36% YoY increase).","FY 2023 revenue estimated $18.1-18.3M, up from $12.9M in FY 2022 (40-42% YoY increase).","Cash at Dec 31, 2023 estimated $8.6M vs $20.5M a year ago; Q4 cash burn improved to $1.7M from $3.6M.","CEO cited strong demand for EksoNR and Indego; final results expected in March 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":18279000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261680,"accession_number":"0001437749-23-031974","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ekso Bionics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq written notice on Nov 14, 2023, confirming compliance with $1.00 minimum bid price rule.","Previous deficiency notice was received on Sept 29, 2023, for 30 consecutive business days below $1.00.","Nasdaq has closed the matter; no further delisting risk from this issue.","Common stock continues trading on Nasdaq Capital Market under ticker EKSO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261679,"accession_number":"0001437749-23-029094","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ekso Bionics Q3 revenue up 38% to $4.6M; net loss narrows to $0.24/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $4.6M, up 38% YoY; gross margin improved to 53% from 51%.","Net loss narrowed to $3.4M ($0.24 per share) from $4.3M ($0.33) in Q3 2022.","Sold 41 EksoHealth devices, including a record quarter of EVO unit sales.","Cash on hand $9.9M at Sep 30, 2023, down from $20.5M at Dec 31, 2022.","Company applied for CMS code determination for Indego Personal exoskeleton."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":13432000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278901,"accession_number":"0001437749-23-027198","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["1.01","3.01"],"status":"ready","headline":"Ekso Bionics receives $700K from Parker-Hannifin; Nasdaq gives bid price deficiency notice","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received $700,000 from Parker-Hannifin in settlement of warranty obligations under Asset Purchase Agreement.","Nasdaq notified Ekso that common stock bid price below $1.00 for 30 consecutive business days.","Company has 180 days, until March 27, 2024, to regain compliance by closing at $1.00 for 10 consecutive days.","If not compliant, may seek second 180-day period via reverse stock split or other cure.","Notice has no immediate effect on listing; company intends to monitor and consider options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278900,"accession_number":"0001549084-23-000059","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2023-08-18T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Ekso Bionics amends loan: extends maturity to 2026, interest at prime or 4.5% min","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Term Loan interest set to greater of Pacific Western Bank prime rate or 4.50% annually.","Term Loan maturity date extended from original to August 13, 2026.","Borrower must move all depository accounts to Pacific Western and close JPMorgan accounts within 30 days.","Pays $2,000 facility fee and reimburses Bank expenses for the amendment.","Company represents no Event of Default exists as of the amendment date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278899,"accession_number":"0001437749-23-020966","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2023-07-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ekso Bionics files prospectus to sell up to $5.0M shares in at-the-market offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement under existing ATM agreement with H.C. Wainwright & Co. for up to $5.0M of common stock.","Shares issued under effective S-3 registration statement (No. 333-272607) declared effective June 20, 2023.","Proceeds not specified; general corporate purposes likely."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278898,"accession_number":"0001549084-23-000057","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2023-07-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ekso Bionics Q2 2023 record revenue $4.7M, up 36% YoY; net loss $0.31/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.7M (+36% YoY); gross profit $2.3M (48% margin) vs $1.6M (47%) in Q2 2022.","Net loss $4.2M ($0.31 diluted EPS) vs $3.0M ($0.23) a year ago, driven by HMC acquisition costs.","Booked 44 EksoHealth devices in Q2; cash $13.3M at June 30, 2023 versus $20.5M at Dec 31, 2022.","Sales & marketing $2.3M, R&D $1.4M, G&A $2.8M; all up YoY due to HMC integration and severance.","Six-month 2023 revenue $8.8M (+46% YoY); net loss $8.6M compared to $7.6M in H1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":8825000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297170,"accession_number":"0001104659-23-070425","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["1.01","5.07","9.01"],"status":"ready","headline":"Ekso Bionics removes $6.75 floor from ATM offering; shareholders approve share plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended at-the-market offering agreement with H.C. Wainwright to remove $6.75 per share floor, effective June 12, 2023.","Prior ATM sales: 77,594 shares at avg $10.72 for $791,217 net proceeds; $6.67M remains available.","Shareholders approved 2014 Equity Incentive Plan amendment, increasing authorized shares from 2,524,286 to 3,724,286.","All five director nominees elected; advisory say-on-pay passed with ~4.1M For vs 293K Against.","Ratified WithumSmith+Brown as independent auditor for FY2023 with ~7.0M For votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297169,"accession_number":"0001549084-23-000018","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ekso Bionics Q1 revenues hit record $4.1M, up 61% YoY; net loss narrows to $4.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $4.1M, a 61% increase from $2.6M in Q1 2022; gross margin improved to 49% from 47%.","Net loss of $4.4M ($0.33 per share) vs. $4.6M ($0.36 per share) in Q1 2022.","Booked 23 EksoHealth devices in Q1; cash position $16.3M at March 31, 2023.","Sales & marketing spend rose to $2.1M from $1.6M, reflecting HMC acquisition costs.","CEO cites multi-unit orders with large network operators and Indego product line contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":4122000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297168,"accession_number":"0001549084-23-000015","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Ekso Bionics director Stern resigns; CEO bonus potential raised to 75% of salary","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stanley Stern resigns from board effective April 26, 2023; no disagreement with Company.","Stern's unvested RSUs under 2014 Equity Incentive Plan to fully vest on resignation.","CEO Scott Davis's 2023 bonus potential increased from 50% to 75% of base salary.","Board restated articles to remove Series A Preferred certificate of designations (no shares outstanding).","Bylaws amended to address universal proxy rules and update meeting procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317546,"accession_number":"0001549084-23-000008","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ekso Bionics reports FY 2022 revenue up 15% to $12.9M, net loss widens to $15.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year revenue $12.9M (up 15% YoY); Q4 revenue $3.6M vs $4.1M year ago.","Net loss $15.1M ($1.16 per share) for FY2022, vs $9.8M loss ($0.80 per share) in 2021.","Gross margin declined to 48% from 60% due to higher service, supply chain, and labor costs.","Cash at Dec 31, 2022 was $20.5M, down from $40.4M; operations used $14.7M cash.","Completed acquisition of Parker Hannifin's HMC business (Indego product line); FDA clearance for EksoNR in MS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317545,"accession_number":"0001549084-23-000004","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K/A","filed_at":"2023-02-16T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Ekso Bionics acquires Parker Hannifin's HMC business for $10M; HMC had $2.2M op loss in FY2022","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Dec 5, 2022; purchase price $10M: $5M cash + $5M subordinated zero-coupon note due Sep 2027.","HMC FY2022 (Jun 2022) revenue $4.3M, operating loss $2.2M; FY2021 loss $4.0M on $2.7M revenue.","Pro forma 9mo Sep 2022 combined net loss $14.8M ($1.14 diluted EPS) vs Ekso standalone $11.9M loss.","Preliminary purchase price allocation: $5.2M intangible assets, $0.7M goodwill, $1.0M property step-ups.","HMC unaudited 3mo Sep 2022 revenue $390k, operating loss $1.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335777,"accession_number":"0001549084-22-000080","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2022-12-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ekso Bionics appoints CEO Scott G. Davis to its Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective Dec 8, 2022; term expires at 2023 Annual Meeting.","Davis previously served as President and COO before becoming CEO.","No arrangements or understandings with any person for his board election.","No family relationships or material interest in reportable transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335776,"accession_number":"0001549084-22-000075","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2022-12-05T23:59:59+00:00","items":["2.01","5.02","7.01","9.01"],"status":"ready","headline":"Ekso Bionics acquires Parker HMC business for $10M, appoints Scott Davis as CEO","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired Parker Hannifin's Human Motion and Control business for $10M ($5M cash + $5M zero-coupon note payable quarterly over 4 years).","Acquisition includes Indego lower-limb exoskeleton line, expanding Ekso's product portfolio into home and community use markets.","Steven Sherman resigned as CEO; appointed Scott G. Davis (formerly President/COO) as CEO effective immediately.","Sherman remains Chairman and becomes Executive Chair under a one-year employment agreement with $125k salary and RSU grant.","Adds Vanderbilt University as a key commercial and research partner to support future product development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335775,"accession_number":"0001549084-22-000069","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ekso Bionics Q3 revenue up 9.2% to $3.3M; net loss widens to $4.3M; record 33 EksoNR bookings","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.3M (+9.2% YoY); nine-month revenue $9.4M (+30.6% YoY).","Record bookings of 33 EksoNR units in Q3; driven by increase in international orders.","Gross margin fell to 51% in Q3 from 59% a year ago due to higher service and supply chain costs.","Net loss applicable to common stockholders $4.3M ($0.33 per share) vs $2.0M ($0.15) in Q3 2021.","Cash position $29.2M at Sept 30, 2022, down from $40.4M at Dec 31, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":9361000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335774,"accession_number":"0001549084-22-000065","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2022-10-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ekso Bionics appoints Jerome Wong as permanent CFO, effective Oct 26, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jerome Wong, previously interim CFO since June 2022, appointed permanent CFO, Corporate Secretary and Principal Financial Officer.","Annual salary of $325,000; eligible for bonus up to 50% of base based on company and individual performance.","Receives $250,000 in restricted stock units vesting over three years under the Amended and Restated 2014 Equity Incentive Plan.","If terminated without cause, six months salary continuation severance at base salary rate.","Standard officer indemnification agreement providing indemnification and advancement of expenses to be entered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353210,"accession_number":"0001549084-22-000048","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2022-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ekso Bionics Q2 revenue up 57% to $3.5M; net loss widens to $3.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.5M (+57% YoY); EksoHealth $3.2M, EksoWorks $0.2M; 17 EksoNR units booked.","Net loss $3.0M ($0.23/share) vs $1.3M loss ($0.10) in Q2 2021; gross margin 47% vs 58%.","Received FDA 510(k) clearance for EksoNR for Multiple Sclerosis indication.","Cash $31.9M at June 30, 2022, down from $40.4M at Dec 31, 2021.","Gain on warrant revaluation $1.0M; R&D expense up 30% YoY on next-gen products."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":6032000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370886,"accession_number":"0001549084-22-000029","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"EKSO shareholders approve equity plan share increase and all proposals at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected six directors; average votes for ~4.2M per nominee, with 2.57M broker non-votes each.","Approved equity plan amendment raising authorized shares from 1,974,286 to 2,524,286; 3.9M for, 621k against.","Non-binding say-on-pay approved with 4.24M for, 255k against, 43.6k abstain.","Ratified WithumSmith+Brown as auditor for FY2022 with 6.99M for, 55.7k against.","Approximately 7.1M shares voted of 12.8M outstanding, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-06-10T23:59:59+00:00|370886"}